Yazar "Çelik, Emir" için PubMed İndeksli Yayın Koleksiyonu listeleme
-
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Gürsoy, Pınar; Tatlı, Ali Murat; Erdem, Dilek; Göker, Erdem; Çelik, Emir; Demirci, Nebi Serkan; Yumuk, Perran Fulden; Çavdar, Eyyüp (Springer, 2022)Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ... -
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Bilgin, Burak; Sendur, Mehmet Ali; Yücel, Şebnem; Çelik, Emir; Özyükseler, Deniz Tataroğlu; Ayhan, Murat; Yalçın, Bülent; Avcı, Okan (Springer, 2021)Background The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, ...